InvestorsHub Logo
Post# of 253160
Next 10
Followers 84
Posts 12534
Boards Moderated 0
Alias Born 07/25/2008

Re: None

Saturday, 11/28/2015 9:25:38 PM

Saturday, November 28, 2015 9:25:38 PM

Post# of 253160
Ariad- This interview with Olivier Pilley, GM of Ariad Pharmaceuticals- France, may mark the end of Marty Duvall reign as Ariad's Chief Commercial Officer and Exec. VP as he may have lost control of the troups:

Pilley:

Most recently, we signed a licensing deal with Otsuka. It is remarkable that we were able to command milestone payments from a Big Pharma company, which is indicative of Otsuka’s interest in and commitment to Iclusig®. It is a vote of confidence in us.

Remarkable?

Pilley:

There are three main features of ARIAD I would like to highlight. Firstly, as our model demonstrates, we are very focused on academic rigor and the quality of our scientific research. Haematology is intrinsically one of the most academic areas in medicine and pharmaceuticals, and we are expressly dedicated to the pursuit of quality academic results. This guarantees the effectiveness of our therapies.

Never heard that before..!



http://pharmaboardroom.com/interviews/interview-olivier-pilley-general-manager-ariad-pharmaceuticals-france/
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.